Core Insights - TC BioPharm is participating in the 18th Annual European Life Sciences CEO Forum, with its CEO joining a panel discussion on cancer progress and HealthTech topics [1][2] - The forum will feature over 12 hours of keynotes and panel discussions, taking place on February 26-27, 2025, at the Hilton Zurich Airport Hotel [2] - A global company showcase will include 50+ presentations from various companies seeking investment and partnership opportunities [3] Company Overview - TC BioPharm is a clinical-stage biopharmaceutical company focused on gamma-delta T-cell therapies for cancer treatment, with human efficacy data in acute myeloid leukemia [4] - The company is a leader in developing gamma-delta T cell therapies and is the first to conduct phase II/pivotal clinical studies in oncology [5] - TC BioPharm is conducting two investigator-initiated clinical trials for its unmodified gamma-delta T cell product line, including a Phase 2b/3 pivotal trial for acute myeloid leukemia using its proprietary allogeneic CryoTC technology [5]
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum